Guest guest Posted December 29, 2010 Report Posted December 29, 2010 All, Of interest from Cochrane A. Simpson, DC DABCOMedical Director, Vice PresidentThe CHP Group6600 SW 105th Ave, Suite 115Beaverton, OR 97008503-619-2041 O503-367-0872 C503-644-0442 F Associate Professor; Residency Director, Department of Family Medicine, University of California, IrvineDisclosure: P. Vega, MD, has disclosed no relevant financial relationships. Do Healthy Adults Really Need a Flu Shot? A Best Evidence Review P. Vega, MD Posted: 12/17/2010 Best Evidence Reference Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;7:CD001269. Abstract This study was selected from Medscape Best Evidence, which uses the McMaster Online Rating of Evidence System. Of a possible top score of 7, this study was ranked as 6 for newsworthiness and 6 for relevance by clinicians who used this system. The Background The Centers for Disease Control and Prevention (CDC) now recommends universal vaccination against influenza among adults and children, but is the vaccine effective for healthy individuals? Moreover, can it prevent complications of influenza, which occur less frequently among adults without chronic illness? The current analysis from the Cochrane Database of Systematic Reviews investigates these issues and finds weak evidence of vaccine efficacy. Prevention is a profound theme in medicine. Physicians and patients are constantly in search of therapy that can reduce or eliminate the risk for illness and mortality. Vaccinations are one of the best examples of preventive medicine, and the influenza vaccination is widely used around the globe. The potentially severe consequences of influenza infection, particularly the risk associated with pandemic disease, are well-documented. In the decade prior to 1999, influenza virus was associated with an average of 51,203 deaths per year in the United States.[1] The majority of these deaths were due to respiratory and circulatory illness, and 90% of these fatal cases occurred among adults aged 65 years and older. During a similar period, the annual number of hospitalizations for influenza-related illness exceeded 1 million in the United States.[2] The number of primary influenza and pneumonia hospitalizations among adults aged 85 years and older was nearly double that of individuals between the ages of 5 and 49 years of age. Younger adults may be at lower risk for the complications of influenza, but the infection has a significant impact on them as well. In 1 study of adults between the ages of 50 and 64 years, the prevalence of influenza-like illness during the 2006-2007 season was 17.1%.[3] Among people who didn't receive a flu vaccine, influenza-like illness accounted for 39% of illness-related lost work days and 49% of all days with reduced productivity due to illness. A review of 28 studies found that the average number of work-days lost per episode of physician-diagnosed influenza was 3.7 to 5.9.[4] Laboratory-confirmed influenza resulted in 1.5-4.9 days lost from work. Overall, the annual average direct medical costs related to influenza in the United States exceed $10 billion, and projected lost earnings due to illness and loss of life total $16.3 billion annually.[5] Influenza promotes significant loss of productivity even among young adults. In a study of 3249 college students, 36.7% of participants reported at least 1 influenza-like illness in 2002-2003.[6] Colds and influenza accounted for a total of 45,219 days of illness, and nearly one fourth of participants had sought medical care for their infection. Infections led to 27.8% of participants performing poorly on an examination and 46.3% doing poorly on a class assignment. Influenza-like illness was more likely than colds to affect school performance. The influenza vaccine is frequently cited as a means to reduce morbidity and mortality associated with the infection, and the CDC now calls for universal influenza vaccination for individuals at age 6 months or older.[7] For the first time, these recommendations include healthy adults who are not in contact with individuals at high risk for the complications of influenza. The new recommendation for vaccinating healthy adults is built upon several assumptions: The vaccine will reduce the number of cases of influenza; The vaccine will reduce complications of influenza; The vaccine will reduce the transmission of influenza; and The vaccine will safely accomplish these goals. But does the influenza vaccine fulfill these criteria, particularly for a low-risk group such as healthy adults? The current meta-analysis examines this issue. Current Trial Researchers examined medical databases through June 2010 for randomized controlled trials of influenza vaccines. Nonrandomized trials were included if they provided safety data regarding the vaccine. Researchers focused on trials of individuals between the ages of 16 and 65 years. The main study outcome was the number of infections with influenza and the seriousness of infection symptoms. Researchers also followed rates of influenza complications and the number of working days lost. Finally, the risk for adverse events associated with the influenza vaccine was evaluated. The review included 50 studies. Thirty-four data sets involving a total of 34,573 participants investigated efficacy of the inactivated parenteral influenza vaccine, and 16 data sets provided data on the harms associated with the vaccine. These vaccines were 30% effective in preventing influenza-like illness when the contents of the vaccine matched well with the circulating virus. Vaccine efficacy dropped significantly for symptom prevention when the vaccine was not well-matched to the circulating virus. Overall, when vaccine virus matching was good, influenza-like illness developed in 1% of vaccinated individuals compared with 4% of unvaccinated individuals. The respective infection rates were 1% and 2% when vaccine virus matching was poor. The average time off work saved with the inactivated parenteral influenza vaccine was only 0.13 days. Four trials included hospital admissions as an outcome. Although the rate of hospitalization was lower in comparing vaccinated vs unvaccinated individuals, this difference was not statistically significant. Overall, none of the different influenza vaccines had a significant effect in reducing the risk of complications of influenza among healthy adults. Seven data sets involving a total of 29,955 participants examined the efficacy of the live aerosol vaccine, and 9 data sets reported harms data only. These vaccines had an overall effectiveness of 10%, and vaccine virus matching did not significantly affect their performance. Two studies of the inactivated aerosol vaccine demonstrated good effectiveness of 42%, but the authors of the current meta-analysis caution that this finding is based on a limited amount of data. The relative risk for local tenderness and erythema in comparing the inactivated parenteral influenza vaccine and placebo was 3.11, but vaccination was not associated with induration or arm stiffness. The relative risk for myalgia with active vaccination vs placebo was 1.54, but the parenteral vaccine was not associated with other systemic adverse events. Live aerosol vaccines were associated with significant increases in the risks for upper respiratory infection, sore throat, and coryza. Neither of the trials of the inactivated aerosol vaccines addressed harms. The current study also investigated the risk for serious adverse events associated with the use of the influenza vaccine. The inactivated vaccine may promote an additional 1.6 cases of Guillain-Barré syndrome for each million vaccinations given. An inactivated aerosol vaccine was associated with a profound increase in the risk for Bell's palsy, a finding that prompted the manufacturer to halt production of this particular vaccine. The aerosol vaccine is associated with a nonsignificant temporary decline in pulmonary function, and it should be avoided among patients with asthma.[8] Discussion Overall, the current review finds that the evidence for universal vaccination of all healthy adults is underwhelming. Even when the vaccine was well-matched to the circulating virus, vaccination against influenza was far from fully protective against infection. Moreover, the flu vaccine had a minimal impact on the number of days of work missed, and it did not prevent complications of influenza. Unfortunately, a recent review of influenza vaccination among adults at age 65 or older also suggested that the vaccine was of questionable efficacy.[9] While vaccination appeared to reduce the symptoms of influenza, the heterogeneity and poor quality of the collected research prevented any strong conclusion regarding the effectiveness of the vaccine in preventing complications of influenza in this high-risk population. Analyses from the Cochrane Database of Systematic Reviews regarding the use of the influenza vaccine clearly state a need for better evidence of vaccine efficacy, and they are also quite pointed in their critique of public health efforts to increase the usage of the vaccine. The current article states, " The CDC authors clearly do not weight interpretation by quality of the evidence, but quote anything that supports their theory. " The give-and-take between the reviewers and these agencies does little to improve our collective knowledge regarding the efficacy of the influenza vaccine, nor does it help patients. It is clear that a large trial of vaccine efficacy over several influenza seasons is required. The results could affect millions of lives and potentially save billions in healthcare dollars. Clinical Pearls Influenza rarely promotes significant complications among healthy adult patients, but it does cause significant interruptions from work and healthcare expenditures, even among young adults; The current meta-analysis finds that influenza vaccine efficacy is limited among healthy adults, even during years when the vaccine is well-matched to the circulating virus; The current study also finds that influenza vaccination for healthy adults results in a small improvement in absenteeism from work and no significant effect on the risk for complications of influenza; and Side effects from influenza vaccination are generally not serious. The results of analyses from the Cochrane Database of Systematic Reviews contradict recommendations from large public health organizations for influenza vaccination among all adults. [ CLOSE WINDOW ] References WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186. Abstract WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333-1340. Abstract Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50 - 64 years. Clin Infect Dis. 2009;48:292-298. Abstract Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics. 2008;26:911-924. Abstract Molinari NA, Ortega- IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086-5096. Abstract Nichol KL, D'Heilly SJ, Ehlinger E. Colds and influenza-like illnesses in university students: impact on health, academic and work performance, and heath care use. Clin Infect Dis. 2005;40:1263-1270. Abstract Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunication Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1-62. Fiore AE, Brdges CB, NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol. 2009;333:43-82. Abstract Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;(2):CD004876. Medscape Family Medicine © 2010 WebMD, LLC Quote
Guest guest Posted December 29, 2010 Report Posted December 29, 2010 Thanks Dr. Simpson; I read through this and this paragraph caught my attention: “Overall, when vaccine virus matching was good, influenza-like illness developed in 1% of vaccinated individuals compared with 4% of unvaccinated individuals. The respective infection rates were 1% and 2% when vaccine virus matching was poor.” If I am reading this correctly, when they properly matched the vaccine to the common strains infecting people, only 1% of the people vaccinated got sick while 4% of the non-vaccinated group got sick. However when they did not match the vaccine to the prevalent strains then 1% of the vaccinated group got sick and 2% of the non-vaccinated group got sick. My first thought was, “I only have a 4% chance of getting sick? Then why vaccinate against flu?” Then I re-read this paragraph and I wondered why would there be a difference in the control group (2% and 4%) if the only difference was the accuracy of the strain matching in the vaccine? Modifying this variable should not change the outcomes for the control groups, because the people in the control groups weren’t exposed to the vaccine. The next thing I noticed is that 1% of the people got sick in both the vaccinated groups! Again, assuming I’m reading this correctly, 1% got sick when they matched the correct strain of virus in the vaccine and 1% got sick when they did not match the proper strains. This data would suggest that what strain is used to make the vaccine is immaterial to the outcome. This should call into question which part of the vaccine is actually making any perceived difference. Now I realize that there are some challenges to comparing data from different studies. But these authors were reporting a meta-analysis of 50 studies and over 35,000 patients. My understanding is that a meta-analysis is supposed to “smooth out” the peaks and valleys” caused by outlying data sets. Glenn Sykes, DC Gresham Town Fair Chiropractic Clinic Phone: (503) 667-6744 Fax: (503) 661-7896 WWW.GRESHAMCHIROPRACTOR.NET From: [mailto: ] On Behalf Of Chuck Simpson, DC Sent: Wednesday, December 29, 2010 1:29 PM Subject: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;7:CD001269 All, Of interest from Cochrane A. Simpson, DC DABCO Medical Director, Vice President The CHP Group 6600 SW 105th Ave, Suite 115 Beaverton, OR 97008 503-619-2041 O 503-367-0872 C 503-644-0442 F Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine Disclosure: P. Vega, MD, has disclosed no relevant financial relationships. Do Healthy Adults Really Need a Flu Shot? A Best Evidence Review P. Vega, MD Posted: 12/17/2010 Best Evidence Reference Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;7:CD001269. Abstract This study was selected from Medscape Best Evidence, which uses the McMaster Online Rating of Evidence System. Of a possible top score of 7, this study was ranked as 6 for newsworthiness and 6 for relevance by clinicians who used this system. The Background The Centers for Disease Control and Prevention (CDC) now recommends universal vaccination against influenza among adults and children, but is the vaccine effective for healthy individuals? Moreover, can it prevent complications of influenza, which occur less frequently among adults without chronic illness? The current analysis from the Cochrane Database of Systematic Reviews investigates these issues and finds weak evidence of vaccine efficacy. Prevention is a profound theme in medicine. Physicians and patients are constantly in search of therapy that can reduce or eliminate the risk for illness and mortality. Vaccinations are one of the best examples of preventive medicine, and the influenza vaccination is widely used around the globe. The potentially severe consequences of influenza infection, particularly the risk associated with pandemic disease, are well-documented. In the decade prior to 1999, influenza virus was associated with an average of 51,203 deaths per year in the United States.[1] The majority of these deaths were due to respiratory and circulatory illness, and 90% of these fatal cases occurred among adults aged 65 years and older. During a similar period, the annual number of hospitalizations for influenza-related illness exceeded 1 million in the United States.[2] The number of primary influenza and pneumonia hospitalizations among adults aged 85 years and older was nearly double that of individuals between the ages of 5 and 49 years of age. Younger adults may be at lower risk for the complications of influenza, but the infection has a significant impact on them as well. In 1 study of adults between the ages of 50 and 64 years, the prevalence of influenza-like illness during the 2006-2007 season was 17.1%.[3] Among people who didn't receive a flu vaccine, influenza-like illness accounted for 39% of illness-related lost work days and 49% of all days with reduced productivity due to illness. A review of 28 studies found that the average number of work-days lost per episode of physician-diagnosed influenza was 3.7 to 5.9.[4] Laboratory-confirmed influenza resulted in 1.5-4.9 days lost from work. Overall, the annual average direct medical costs related to influenza in the United States exceed $10 billion, and projected lost earnings due to illness and loss of life total $16.3 billion annually.[5] Influenza promotes significant loss of productivity even among young adults. In a study of 3249 college students, 36.7% of participants reported at least 1 influenza-like illness in 2002-2003.[6] Colds and influenza accounted for a total of 45,219 days of illness, and nearly one fourth of participants had sought medical care for their infection. Infections led to 27.8% of participants performing poorly on an examination and 46.3% doing poorly on a class assignment. Influenza-like illness was more likely than colds to affect school performance. The influenza vaccine is frequently cited as a means to reduce morbidity and mortality associated with the infection, and the CDC now calls for universal influenza vaccination for individuals at age 6 months or older.[7] For the first time, these recommendations include healthy adults who are not in contact with individuals at high risk for the complications of influenza. The new recommendation for vaccinating healthy adults is built upon several assumptions: · The vaccine will reduce the number of cases of influenza; · The vaccine will reduce complications of influenza; · The vaccine will reduce the transmission of influenza; and · The vaccine will safely accomplish these goals. But does the influenza vaccine fulfill these criteria, particularly for a low-risk group such as healthy adults? The current meta-analysis examines this issue. Current Trial Researchers examined medical databases through June 2010 for randomized controlled trials of influenza vaccines. Nonrandomized trials were included if they provided safety data regarding the vaccine. Researchers focused on trials of individuals between the ages of 16 and 65 years. The main study outcome was the number of infections with influenza and the seriousness of infection symptoms. Researchers also followed rates of influenza complications and the number of working days lost. Finally, the risk for adverse events associated with the influenza vaccine was evaluated. The review included 50 studies. Thirty-four data sets involving a total of 34,573 participants investigated efficacy of the inactivated parenteral influenza vaccine, and 16 data sets provided data on the harms associated with the vaccine. These vaccines were 30% effective in preventing influenza-like illness when the contents of the vaccine matched well with the circulating virus. Vaccine efficacy dropped significantly for symptom prevention when the vaccine was not well-matched to the circulating virus. Overall, when vaccine virus matching was good, influenza-like illness developed in 1% of vaccinated individuals compared with 4% of unvaccinated individuals. The respective infection rates were 1% and 2% when vaccine virus matching was poor. The average time off work saved with the inactivated parenteral influenza vaccine was only 0.13 days. Four trials included hospital admissions as an outcome. Although the rate of hospitalization was lower in comparing vaccinated vs unvaccinated individuals, this difference was not statistically significant. Overall, none of the different influenza vaccines had a significant effect in reducing the risk of complications of influenza among healthy adults. Seven data sets involving a total of 29,955 participants examined the efficacy of the live aerosol vaccine, and 9 data sets reported harms data only. These vaccines had an overall effectiveness of 10%, and vaccine virus matching did not significantly affect their performance. Two studies of the inactivated aerosol vaccine demonstrated good effectiveness of 42%, but the authors of the current meta-analysis caution that this finding is based on a limited amount of data. The relative risk for local tenderness and erythema in comparing the inactivated parenteral influenza vaccine and placebo was 3.11, but vaccination was not associated with induration or arm stiffness. The relative risk for myalgia with active vaccination vs placebo was 1.54, but the parenteral vaccine was not associated with other systemic adverse events. Live aerosol vaccines were associated with significant increases in the risks for upper respiratory infection, sore throat, and coryza. Neither of the trials of the inactivated aerosol vaccines addressed harms. The current study also investigated the risk for serious adverse events associated with the use of the influenza vaccine. The inactivated vaccine may promote an additional 1.6 cases of Guillain-Barré syndrome for each million vaccinations given. An inactivated aerosol vaccine was associated with a profound increase in the risk for Bell's palsy, a finding that prompted the manufacturer to halt production of this particular vaccine. The aerosol vaccine is associated with a nonsignificant temporary decline in pulmonary function, and it should be avoided among patients with asthma.[8] Discussion Overall, the current review finds that the evidence for universal vaccination of all healthy adults is underwhelming. Even when the vaccine was well-matched to the circulating virus, vaccination against influenza was far from fully protective against infection. Moreover, the flu vaccine had a minimal impact on the number of days of work missed, and it did not prevent complications of influenza. Unfortunately, a recent review of influenza vaccination among adults at age 65 or older also suggested that the vaccine was of questionable efficacy.[9] While vaccination appeared to reduce the symptoms of influenza, the heterogeneity and poor quality of the collected research prevented any strong conclusion regarding the effectiveness of the vaccine in preventing complications of influenza in this high-risk population. Analyses from the Cochrane Database of Systematic Reviews regarding the use of the influenza vaccine clearly state a need for better evidence of vaccine efficacy, and they are also quite pointed in their critique of public health efforts to increase the usage of the vaccine. The current article states, " The CDC authors clearly do not weight interpretation by quality of the evidence, but quote anything that supports their theory. " The give-and-take between the reviewers and these agencies does little to improve our collective knowledge regarding the efficacy of the influenza vaccine, nor does it help patients. It is clear that a large trial of vaccine efficacy over several influenza seasons is required. The results could affect millions of lives and potentially save billions in healthcare dollars. Clinical Pearls · Influenza rarely promotes significant complications among healthy adult patients, but it does cause significant interruptions from work and healthcare expenditures, even among young adults; · The current meta-analysis finds that influenza vaccine efficacy is limited among healthy adults, even during years when the vaccine is well-matched to the circulating virus; · The current study also finds that influenza vaccination for healthy adults results in a small improvement in absenteeism from work and no significant effect on the risk for complications of influenza; and · Side effects from influenza vaccination are generally not serious. The results of analyses from the Cochrane Database of Systematic Reviews contradict recommendations from large public health organizations for influenza vaccination among all adults. [ CLOSE WINDOW ] References 1. WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186. Abstract 2. WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333-1340. Abstract 3. Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50 - 64 years. Clin Infect Dis. 2009;48:292-298. Abstract 4. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics. 2008;26:911-924. Abstract 5. Molinari NA, Ortega- IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086-5096. Abstract 6. Nichol KL, D'Heilly SJ, Ehlinger E. Colds and influenza-like illnesses in university students: impact on health, academic and work performance, and heath care use. Clin Infect Dis. 2005;40:1263-1270. Abstract 7. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunication Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1-62. 8. Fiore AE, Brdges CB, NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol. 2009;333:43-82. Abstract 9. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;(2):CD004876. Medscape Family Medicine © 2010 WebMD, LLC __________ Information from ESET NOD32 Antivirus, version of virus signature database 5734 (20101226) __________ The message was checked by ESET NOD32 Antivirus. http://www.eset.com __________ Information from ESET NOD32 Antivirus, version of virus signature database 5734 (20101226) __________ The message was checked by ESET NOD32 Antivirus. http://www.eset.com Quote
Guest guest Posted December 29, 2010 Report Posted December 29, 2010 Thanks Dr. Simpson; I read through this and this paragraph caught my attention: “Overall, when vaccine virus matching was good, influenza-like illness developed in 1% of vaccinated individuals compared with 4% of unvaccinated individuals. The respective infection rates were 1% and 2% when vaccine virus matching was poor.” If I am reading this correctly, when they properly matched the vaccine to the common strains infecting people, only 1% of the people vaccinated got sick while 4% of the non-vaccinated group got sick. However when they did not match the vaccine to the prevalent strains then 1% of the vaccinated group got sick and 2% of the non-vaccinated group got sick. My first thought was, “I only have a 4% chance of getting sick? Then why vaccinate against flu?” Then I re-read this paragraph and I wondered why would there be a difference in the control group (2% and 4%) if the only difference was the accuracy of the strain matching in the vaccine? Modifying this variable should not change the outcomes for the control groups, because the people in the control groups weren’t exposed to the vaccine. The next thing I noticed is that 1% of the people got sick in both the vaccinated groups! Again, assuming I’m reading this correctly, 1% got sick when they matched the correct strain of virus in the vaccine and 1% got sick when they did not match the proper strains. This data would suggest that what strain is used to make the vaccine is immaterial to the outcome. This should call into question which part of the vaccine is actually making any perceived difference. Now I realize that there are some challenges to comparing data from different studies. But these authors were reporting a meta-analysis of 50 studies and over 35,000 patients. My understanding is that a meta-analysis is supposed to “smooth out” the peaks and valleys” caused by outlying data sets. Glenn Sykes, DC Gresham Town Fair Chiropractic Clinic Phone: (503) 667-6744 Fax: (503) 661-7896 WWW.GRESHAMCHIROPRACTOR.NET From: [mailto: ] On Behalf Of Chuck Simpson, DC Sent: Wednesday, December 29, 2010 1:29 PM Subject: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;7:CD001269 All, Of interest from Cochrane A. Simpson, DC DABCO Medical Director, Vice President The CHP Group 6600 SW 105th Ave, Suite 115 Beaverton, OR 97008 503-619-2041 O 503-367-0872 C 503-644-0442 F Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine Disclosure: P. Vega, MD, has disclosed no relevant financial relationships. Do Healthy Adults Really Need a Flu Shot? A Best Evidence Review P. Vega, MD Posted: 12/17/2010 Best Evidence Reference Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;7:CD001269. Abstract This study was selected from Medscape Best Evidence, which uses the McMaster Online Rating of Evidence System. Of a possible top score of 7, this study was ranked as 6 for newsworthiness and 6 for relevance by clinicians who used this system. The Background The Centers for Disease Control and Prevention (CDC) now recommends universal vaccination against influenza among adults and children, but is the vaccine effective for healthy individuals? Moreover, can it prevent complications of influenza, which occur less frequently among adults without chronic illness? The current analysis from the Cochrane Database of Systematic Reviews investigates these issues and finds weak evidence of vaccine efficacy. Prevention is a profound theme in medicine. Physicians and patients are constantly in search of therapy that can reduce or eliminate the risk for illness and mortality. Vaccinations are one of the best examples of preventive medicine, and the influenza vaccination is widely used around the globe. The potentially severe consequences of influenza infection, particularly the risk associated with pandemic disease, are well-documented. In the decade prior to 1999, influenza virus was associated with an average of 51,203 deaths per year in the United States.[1] The majority of these deaths were due to respiratory and circulatory illness, and 90% of these fatal cases occurred among adults aged 65 years and older. During a similar period, the annual number of hospitalizations for influenza-related illness exceeded 1 million in the United States.[2] The number of primary influenza and pneumonia hospitalizations among adults aged 85 years and older was nearly double that of individuals between the ages of 5 and 49 years of age. Younger adults may be at lower risk for the complications of influenza, but the infection has a significant impact on them as well. In 1 study of adults between the ages of 50 and 64 years, the prevalence of influenza-like illness during the 2006-2007 season was 17.1%.[3] Among people who didn't receive a flu vaccine, influenza-like illness accounted for 39% of illness-related lost work days and 49% of all days with reduced productivity due to illness. A review of 28 studies found that the average number of work-days lost per episode of physician-diagnosed influenza was 3.7 to 5.9.[4] Laboratory-confirmed influenza resulted in 1.5-4.9 days lost from work. Overall, the annual average direct medical costs related to influenza in the United States exceed $10 billion, and projected lost earnings due to illness and loss of life total $16.3 billion annually.[5] Influenza promotes significant loss of productivity even among young adults. In a study of 3249 college students, 36.7% of participants reported at least 1 influenza-like illness in 2002-2003.[6] Colds and influenza accounted for a total of 45,219 days of illness, and nearly one fourth of participants had sought medical care for their infection. Infections led to 27.8% of participants performing poorly on an examination and 46.3% doing poorly on a class assignment. Influenza-like illness was more likely than colds to affect school performance. The influenza vaccine is frequently cited as a means to reduce morbidity and mortality associated with the infection, and the CDC now calls for universal influenza vaccination for individuals at age 6 months or older.[7] For the first time, these recommendations include healthy adults who are not in contact with individuals at high risk for the complications of influenza. The new recommendation for vaccinating healthy adults is built upon several assumptions: · The vaccine will reduce the number of cases of influenza; · The vaccine will reduce complications of influenza; · The vaccine will reduce the transmission of influenza; and · The vaccine will safely accomplish these goals. But does the influenza vaccine fulfill these criteria, particularly for a low-risk group such as healthy adults? The current meta-analysis examines this issue. Current Trial Researchers examined medical databases through June 2010 for randomized controlled trials of influenza vaccines. Nonrandomized trials were included if they provided safety data regarding the vaccine. Researchers focused on trials of individuals between the ages of 16 and 65 years. The main study outcome was the number of infections with influenza and the seriousness of infection symptoms. Researchers also followed rates of influenza complications and the number of working days lost. Finally, the risk for adverse events associated with the influenza vaccine was evaluated. The review included 50 studies. Thirty-four data sets involving a total of 34,573 participants investigated efficacy of the inactivated parenteral influenza vaccine, and 16 data sets provided data on the harms associated with the vaccine. These vaccines were 30% effective in preventing influenza-like illness when the contents of the vaccine matched well with the circulating virus. Vaccine efficacy dropped significantly for symptom prevention when the vaccine was not well-matched to the circulating virus. Overall, when vaccine virus matching was good, influenza-like illness developed in 1% of vaccinated individuals compared with 4% of unvaccinated individuals. The respective infection rates were 1% and 2% when vaccine virus matching was poor. The average time off work saved with the inactivated parenteral influenza vaccine was only 0.13 days. Four trials included hospital admissions as an outcome. Although the rate of hospitalization was lower in comparing vaccinated vs unvaccinated individuals, this difference was not statistically significant. Overall, none of the different influenza vaccines had a significant effect in reducing the risk of complications of influenza among healthy adults. Seven data sets involving a total of 29,955 participants examined the efficacy of the live aerosol vaccine, and 9 data sets reported harms data only. These vaccines had an overall effectiveness of 10%, and vaccine virus matching did not significantly affect their performance. Two studies of the inactivated aerosol vaccine demonstrated good effectiveness of 42%, but the authors of the current meta-analysis caution that this finding is based on a limited amount of data. The relative risk for local tenderness and erythema in comparing the inactivated parenteral influenza vaccine and placebo was 3.11, but vaccination was not associated with induration or arm stiffness. The relative risk for myalgia with active vaccination vs placebo was 1.54, but the parenteral vaccine was not associated with other systemic adverse events. Live aerosol vaccines were associated with significant increases in the risks for upper respiratory infection, sore throat, and coryza. Neither of the trials of the inactivated aerosol vaccines addressed harms. The current study also investigated the risk for serious adverse events associated with the use of the influenza vaccine. The inactivated vaccine may promote an additional 1.6 cases of Guillain-Barré syndrome for each million vaccinations given. An inactivated aerosol vaccine was associated with a profound increase in the risk for Bell's palsy, a finding that prompted the manufacturer to halt production of this particular vaccine. The aerosol vaccine is associated with a nonsignificant temporary decline in pulmonary function, and it should be avoided among patients with asthma.[8] Discussion Overall, the current review finds that the evidence for universal vaccination of all healthy adults is underwhelming. Even when the vaccine was well-matched to the circulating virus, vaccination against influenza was far from fully protective against infection. Moreover, the flu vaccine had a minimal impact on the number of days of work missed, and it did not prevent complications of influenza. Unfortunately, a recent review of influenza vaccination among adults at age 65 or older also suggested that the vaccine was of questionable efficacy.[9] While vaccination appeared to reduce the symptoms of influenza, the heterogeneity and poor quality of the collected research prevented any strong conclusion regarding the effectiveness of the vaccine in preventing complications of influenza in this high-risk population. Analyses from the Cochrane Database of Systematic Reviews regarding the use of the influenza vaccine clearly state a need for better evidence of vaccine efficacy, and they are also quite pointed in their critique of public health efforts to increase the usage of the vaccine. The current article states, " The CDC authors clearly do not weight interpretation by quality of the evidence, but quote anything that supports their theory. " The give-and-take between the reviewers and these agencies does little to improve our collective knowledge regarding the efficacy of the influenza vaccine, nor does it help patients. It is clear that a large trial of vaccine efficacy over several influenza seasons is required. The results could affect millions of lives and potentially save billions in healthcare dollars. Clinical Pearls · Influenza rarely promotes significant complications among healthy adult patients, but it does cause significant interruptions from work and healthcare expenditures, even among young adults; · The current meta-analysis finds that influenza vaccine efficacy is limited among healthy adults, even during years when the vaccine is well-matched to the circulating virus; · The current study also finds that influenza vaccination for healthy adults results in a small improvement in absenteeism from work and no significant effect on the risk for complications of influenza; and · Side effects from influenza vaccination are generally not serious. The results of analyses from the Cochrane Database of Systematic Reviews contradict recommendations from large public health organizations for influenza vaccination among all adults. [ CLOSE WINDOW ] References 1. WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186. Abstract 2. WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333-1340. Abstract 3. Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50 - 64 years. Clin Infect Dis. 2009;48:292-298. Abstract 4. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics. 2008;26:911-924. Abstract 5. Molinari NA, Ortega- IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086-5096. Abstract 6. Nichol KL, D'Heilly SJ, Ehlinger E. Colds and influenza-like illnesses in university students: impact on health, academic and work performance, and heath care use. Clin Infect Dis. 2005;40:1263-1270. Abstract 7. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunication Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1-62. 8. Fiore AE, Brdges CB, NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol. 2009;333:43-82. Abstract 9. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;(2):CD004876. Medscape Family Medicine © 2010 WebMD, LLC __________ Information from ESET NOD32 Antivirus, version of virus signature database 5734 (20101226) __________ The message was checked by ESET NOD32 Antivirus. http://www.eset.com __________ Information from ESET NOD32 Antivirus, version of virus signature database 5734 (20101226) __________ The message was checked by ESET NOD32 Antivirus. http://www.eset.com Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.